On February 18, 2025, the Department of New Experimental Therapeutics and Early-Phase 1 Drug Development Service at Kansai Medical University Hospital administered the investigational agent INCA33890—developed by Incyte Corporation (USA)—to the “first patient in Asia” as part of a global, multicenter First-in-Human Phase 1 clinical trial (ClinicalTrials.gov ID: NCT05836324). The administration took place in Kansai Medical University Hospital.
Study Details | A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | ClinicalTrials.gov